NASDAQ:NCNA NuCana (NCNA) Stock Price, News & Analysis $0.99 0.00 (0.00%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$1.00 +0.01 (+0.98%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About NuCana Stock (NASDAQ:NCNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NuCana alerts:Sign Up Key Stats Today's Range$0.96▼$1.0250-Day Range$0.96▼$1.7652-Week Range$0.95▼$4.55Volume27,089 shsAverage Volume256,308 shsMarket Capitalization$4.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview NuCana plc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company applies its ProTide technology platform to existing nucleoside analogues, with the goal of improving their delivery into tumor cells, increasing anticancer activity and overcoming mechanisms of drug resistance. NuCana’s pipeline has included Acelarin (NUC-1031), a ProTide-based version of gemcitabine investigated in several solid tumors, including pancreatic, biliary tract and ovarian cancers. The company has also developed NUC-3373, a ProTide analogue of 5-fluorouracil, and NUC-7738, an investigational cancer therapy derived from a nucleoside analogue. These candidates have been evaluated in clinical studies, but NuCana has not reported a marketed commercial product. NuCana was founded in 2008 and is headquartered in Edinburgh, Scotland. Its drug-development activities have involved clinical research in the United Kingdom, the United States and other international markets. The company has been led by Hugh Griffith, its chief executive officer and a co-founder, alongside a management and scientific team focused on oncology drug development.AI Generated. May Contain Errors. Read More NuCana Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreNCNA MarketRank™: 0.861952406705 of 5 starsNuCana scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingNuCana has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageNuCana has only been the subject of 1 research reports in the past 90 days.Read more about NuCana's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NuCana is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NuCana is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuCana has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about NuCana's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.49% of the float of NuCana has been sold short.Short Interest Ratio / Days to CoverNuCana has a short interest ratio ("days to cover") of 0.31, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NuCana has recently decreased by 6.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuCana does not currently pay a dividend.Dividend GrowthNuCana does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows3 people have added NuCana to their MarketBeat watchlist in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NuCana insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NuCana's insider trading history. Receive NCNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NCNA Stock News HeadlinesNuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in EuropeSeptember 30, 2026 | globenewswire.comNuCana Files Q2 2026 Results and Updates U.S. Registration StatementsAugust 16, 2026 | theglobeandmail.comForget the AI predictions. Look at the incomeAI predictions are everywhere, but Tim Plaehn is focused on something concrete: income. He's found a small AI fund paying investors every single Thursday, up to $1,051 a month. While others debate AI's future, this fund is already paying out now. | Investors Alley (Ad)NuCana Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 13, 2026 | globenewswire.comNuCana plc Sponsored ADRJune 16, 2026 | edition.cnn.comNuCana Appoints Ian Webster as Chief Financial OfficerJune 1, 2026 | globenewswire.comNuCana Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14, 2026 | globenewswire.comNuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029March 22, 2026 | theglobeandmail.comSee More Headlines NCNA Stock Analysis - Frequently Asked Questions How have NCNA shares performed this year? NuCana's stock was trading at $3.60 on January 1st, 2026. Since then, NCNA shares have decreased by 72.6% and is now trading at $0.9853. How were NuCana's earnings last quarter? NuCana PLC Sponsored ADR (NASDAQ:NCNA) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.65) by $1.66. When did NuCana's stock split? Shares of NuCana reverse split on Friday, August 8th 2025.The 1-200 reverse split was announced on Friday, July 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did NuCana IPO? NuCana (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,667,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager. How do I buy shares of NuCana? Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NuCana own? Based on aggregate information from My MarketBeat watchlists, some other companies that NuCana investors own include NVIDIA (NVDA), Plug Power (PLUG), Palantir Technologies (PLTR), Pinterest (PINS), Advanced Micro Devices (AMD), PayPal (PYPL) and Tesla (TSLA). Company Calendar Last Earnings8/13/2026Today10/26/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 NCNA's financial health is in the Red zone, according to TradeSmith. NCNA has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NCNA CIK1709626 Webwww.nucana.com Phone441313571111FaxN/AEmployees11Year Founded2008Profitability EPS (Trailing Twelve Months)($3.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.71 million Net MarginsN/A Pretax MarginN/A Return on Equity-41.90% Return on Assets-33.69% Debt Debt-to-Equity RatioN/A Current Ratio4.73 Quick Ratio4.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.71 per share Price / Book0.13Miscellaneous Outstanding Shares4,160,000Free Float2,863,000Market Cap$4.10 million OptionableNot Optionable Beta2.30 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:NCNA) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredForget the AI predictions. Look at the incomeAI predictions are everywhere, but Tim Plaehn is focused on something concrete: income. He's found a small ...Investors Alley | SponsoredFinally… options made simpleIan Cooper once believed successful options trading meant endless chart-watching, complex strategies, and big ...TradeWins | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
